Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wan-Jen Hong

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Blood Advances|September 1, 2021
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myelomaLuciano J Costa, Faith E Davies, Gregory P Monohan, et al.
Blood Cancer Discovery|November 15, 2021
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-ReactivityRebecca M Richards, Feifei Zhao, Katherine A Freitas, et al.
American Journal of Hematology|December 28, 2020
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myelomaJonathan L Kaufman, Cristina Gasparetto, Fredrik H Schjesvold, et al.
The Lancet. Oncology|November 1, 2020
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2019
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II StudyAndrew H Wei, Stephen A Strickland, Jing-Zhou Hou, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Blood Advances|September 1, 2021
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myelomaLuciano J Costa, Faith E Davies, Gregory P Monohan, et al.
Blood Cancer Discovery|November 15, 2021
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-ReactivityRebecca M Richards, Feifei Zhao, Katherine A Freitas, et al.
American Journal of Hematology|December 28, 2020
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myelomaJonathan L Kaufman, Cristina Gasparetto, Fredrik H Schjesvold, et al.
The Lancet. Oncology|November 1, 2020
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2019
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II StudyAndrew H Wei, Stephen A Strickland, Jing-Zhou Hou, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Pageof 3